AU2017272804B2 - Antibodies to alpha-synuclein and uses thereof - Google Patents

Antibodies to alpha-synuclein and uses thereof Download PDF

Info

Publication number
AU2017272804B2
AU2017272804B2 AU2017272804A AU2017272804A AU2017272804B2 AU 2017272804 B2 AU2017272804 B2 AU 2017272804B2 AU 2017272804 A AU2017272804 A AU 2017272804A AU 2017272804 A AU2017272804 A AU 2017272804A AU 2017272804 B2 AU2017272804 B2 AU 2017272804B2
Authority
AU
Australia
Prior art keywords
ser
gly
val
seq
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017272804A
Other languages
English (en)
Other versions
AU2017272804A1 (en
Inventor
Lorraine IRVING
Michael PERKINTON
Darren Schofield
George THOM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2017272804A1 publication Critical patent/AU2017272804A1/en
Application granted granted Critical
Publication of AU2017272804B2 publication Critical patent/AU2017272804B2/en
Priority to AU2024200601A priority Critical patent/AU2024200601A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
AU2017272804A 2016-06-02 2017-06-01 Antibodies to alpha-synuclein and uses thereof Active AU2017272804B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024200601A AU2024200601A1 (en) 2016-06-02 2024-01-31 Antibodies to alpha-synuclein and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344746P 2016-06-02 2016-06-02
US62/344,746 2016-06-02
PCT/EP2017/063406 WO2017207739A1 (en) 2016-06-02 2017-06-01 Antibodies to alpha-synuclein and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200601A Division AU2024200601A1 (en) 2016-06-02 2024-01-31 Antibodies to alpha-synuclein and uses thereof

Publications (2)

Publication Number Publication Date
AU2017272804A1 AU2017272804A1 (en) 2018-12-13
AU2017272804B2 true AU2017272804B2 (en) 2023-11-23

Family

ID=59021492

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017272804A Active AU2017272804B2 (en) 2016-06-02 2017-06-01 Antibodies to alpha-synuclein and uses thereof
AU2024200601A Pending AU2024200601A1 (en) 2016-06-02 2024-01-31 Antibodies to alpha-synuclein and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024200601A Pending AU2024200601A1 (en) 2016-06-02 2024-01-31 Antibodies to alpha-synuclein and uses thereof

Country Status (37)

Country Link
US (5) US10160800B2 (enExample)
EP (2) EP4000632A1 (enExample)
JP (4) JP7078552B2 (enExample)
KR (1) KR102499438B1 (enExample)
CN (2) CN109475616B (enExample)
AR (1) AR108663A1 (enExample)
AU (2) AU2017272804B2 (enExample)
BR (1) BR112018074978A2 (enExample)
CA (1) CA3025987A1 (enExample)
CL (1) CL2018003438A1 (enExample)
CO (1) CO2018014010A2 (enExample)
CY (1) CY1124896T1 (enExample)
DK (1) DK3463435T3 (enExample)
EA (2) EA202191380A1 (enExample)
EC (1) ECSP18096095A (enExample)
ES (1) ES2903402T3 (enExample)
GE (2) GEP20217253B (enExample)
HR (1) HRP20211935T1 (enExample)
HU (1) HUE057214T2 (enExample)
IL (1) IL263243A (enExample)
LT (1) LT3463435T (enExample)
MA (1) MA45125B1 (enExample)
MD (1) MD3463435T2 (enExample)
MX (1) MX393740B (enExample)
MY (1) MY188183A (enExample)
PE (2) PE20250392A1 (enExample)
PH (1) PH12018502538A1 (enExample)
PL (1) PL3463435T3 (enExample)
PT (1) PT3463435T (enExample)
RS (1) RS62682B1 (enExample)
SG (1) SG11201810420YA (enExample)
SI (1) SI3463435T1 (enExample)
SM (1) SMT202200008T1 (enExample)
TW (2) TW202309093A (enExample)
UA (1) UA124733C2 (enExample)
WO (1) WO2017207739A1 (enExample)
ZA (1) ZA201808582B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
RU2019114679A (ru) 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
EP3555127B1 (en) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
BR112021006123A2 (pt) * 2018-10-19 2021-07-20 Janssen Vaccines & Prevention B.V. anticorpos anti-sinucleína
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
CA3133909A1 (en) 2019-04-18 2020-10-22 Elpida TSIKA Novel molecules for therapy and diagnosis
CN110172098B (zh) * 2019-05-27 2023-03-10 长春工业大学 抗α-突触核蛋白的单克隆抗体及其应用
WO2021055881A1 (en) 2019-09-20 2021-03-25 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof
KR102239512B1 (ko) * 2020-09-10 2021-04-12 서울대학교산학협력단 다중기능성 마이크로캡슐 조성물 및 그 제조방법
WO2022079297A1 (en) 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis
CN112920274A (zh) * 2021-03-17 2021-06-08 江苏贝格尔生物医药有限公司 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用
CN113912716B (zh) * 2021-12-15 2022-03-01 北京凯祥弘康生物科技有限公司 针对α-突触核蛋白抗原的抗体及其应用
US20240279316A1 (en) 2022-12-29 2024-08-22 Astrazeneca Ab Compositions and methods for treating alpha-synucleinopathies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103472A2 (en) * 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2011104696A1 (en) * 2010-02-26 2011-09-01 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
WO2014132210A1 (en) * 2013-02-28 2014-09-04 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2015075011A1 (en) * 2013-11-21 2015-05-28 F. Hoffmann-La Roche Ag ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2361704C (en) 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
DK2361928T3 (en) 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
EP1943341A4 (en) 2005-09-27 2010-07-07 Ca Nat Research Council BLOOD-BRAIN-SPEED-EPITOPES AND USES THEREOF
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP4934074B2 (ja) 2007-03-07 2012-05-16 株式会社アルファ スイッチ固定構造
ES2709048T3 (es) 2008-04-29 2019-04-15 Bioarctic Ab Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
JP4654348B1 (ja) 2010-02-23 2011-03-16 多摩川精機株式会社 検出装置用巻線の正弦波巻線方法
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
EP2771031B1 (en) 2011-10-28 2018-04-18 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
RS62003B2 (sr) 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103472A2 (en) * 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2011104696A1 (en) * 2010-02-26 2011-09-01 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
WO2014132210A1 (en) * 2013-02-28 2014-09-04 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2015075011A1 (en) * 2013-11-21 2015-05-28 F. Hoffmann-La Roche Ag ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE

Also Published As

Publication number Publication date
SG11201810420YA (en) 2018-12-28
MY188183A (en) 2021-11-24
EA038358B1 (ru) 2021-08-13
KR20190013923A (ko) 2019-02-11
GEAP202114964A (en) 2021-01-25
US20250263477A1 (en) 2025-08-21
KR102499438B1 (ko) 2023-02-14
US20190276522A1 (en) 2019-09-12
BR112018074978A2 (pt) 2019-03-12
UA124733C2 (uk) 2021-11-10
AR108663A1 (es) 2018-09-12
EA201892548A1 (ru) 2019-06-28
LT3463435T (lt) 2021-12-27
TW202309093A (zh) 2023-03-01
TW201802119A (zh) 2018-01-16
CL2018003438A1 (es) 2019-03-22
MD3463435T2 (ro) 2022-03-31
MX393740B (es) 2025-03-24
EP3463435A1 (en) 2019-04-10
GEP20217253B (en) 2021-05-13
CY1124896T1 (el) 2023-01-05
TWI765890B (zh) 2022-06-01
US20180002411A1 (en) 2018-01-04
AU2024200601A1 (en) 2024-04-18
US20210179698A1 (en) 2021-06-17
EA202191380A1 (ru) 2021-08-26
MA45125A (fr) 2021-06-02
JP2022110117A (ja) 2022-07-28
PL3463435T3 (pl) 2022-02-14
WO2017207739A1 (en) 2017-12-07
ECSP18096095A (es) 2019-01-31
ZA201808582B (en) 2021-08-25
US20230331830A1 (en) 2023-10-19
PH12018502538A1 (en) 2019-04-08
CN109475616A (zh) 2019-03-15
CN109475616B (zh) 2022-10-18
CA3025987A1 (en) 2017-12-07
AU2017272804A1 (en) 2018-12-13
SI3463435T1 (sl) 2022-02-28
JP2024123247A (ja) 2024-09-10
US10889639B2 (en) 2021-01-12
MA45125B1 (fr) 2021-11-30
PE20190440A1 (es) 2019-03-27
HUE057214T2 (hu) 2022-04-28
ES2903402T3 (es) 2022-04-01
NZ748616A (en) 2025-08-29
SMT202200008T1 (it) 2022-03-21
DK3463435T3 (da) 2021-11-22
PT3463435T (pt) 2021-11-22
US10160800B2 (en) 2018-12-25
US11560424B2 (en) 2023-01-24
EP3463435B1 (en) 2021-10-13
IL263243A (en) 2018-12-31
CN116120445A (zh) 2023-05-16
PE20250392A1 (es) 2025-02-11
CO2018014010A2 (es) 2019-01-18
JP2019527194A (ja) 2019-09-26
HRP20211935T1 (hr) 2022-03-18
JP7823118B2 (ja) 2026-03-03
EP4000632A1 (en) 2022-05-25
MX2018014456A (es) 2019-08-12
RS62682B1 (sr) 2021-12-31
JP2026086794A (ja) 2026-05-26
JP7078552B2 (ja) 2022-05-31

Similar Documents

Publication Publication Date Title
US20250263477A1 (en) Antibodies to alpha-synuclein and uses thereof
AU2017267793B2 (en) Single chain variable fragment CD3 binding proteins
AU2017295608B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
AU2017384681B2 (en) Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JP6952827B2 (ja) 血液脳関門輸送分子およびそれらの使用
AU2021273240B2 (en) Anti-tigit antibody and preparation method and application thereof
AU2017256786B2 (en) Binding molecules specific for FcγGamma RIIA and uses thereof
AU2017231833B2 (en) ILT7 binding molecules and methods of using the same
JP2022506719A (ja) タウ認識抗体
AU2017296094B2 (en) Anti-IL-22R antibodies
AU2020291487B2 (en) Bispecific antibody against alpha-syn/IGF1R and use thereof
HK40072606A (en) Antibodies to alpha-synuclein and uses thereof
CA3119072A1 (en) Antibodies recognizing tau
HK40093237A (en) Antibodies to alpha-synuclein and uses thereof
HK40007492B (en) Antibodies to alpha-synuclein and uses thereof
HK40005896B (zh) 针对α-突触核蛋白的抗体及其用途
HK40005896A (en) Antibodies to alpha-synuclein and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)